Alivus Life Sciences Ratios

Alivus Life Sciences Ltd Ratios

The Alivus Life Sciences Ltd Ratios page provides a complete fundamental analysis of Alivus Life Sciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Alivus Life Sciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Alivus Life Sciences Ltd (NSE: ALIVUS, BSE: 543322) is currently trading at ₹1044.95, with a market capitalization of ₹128.92B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Alivus Life Sciences Ltd remains a key stock for fundamental analysis using Alivus Life Sciences Ltd Ratios.

Alivus Life Sciences Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Alivus Life Sciences Ltd P/E ratio currently stands at 27.32, making it one of the most tracked metrics in Alivus Life Sciences Ltd Ratios.

Historically, the Alivus Life Sciences Ltd P/E ratio has shown strong fluctuations:

• 2024: 27.32
• 2023: 20.20
• 2022: 10.28
• 2021: 12.88
• 2020: 0

The rising Alivus Life Sciences Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Alivus Life Sciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 4.70.

Historical P/B trend:

• 2024: 4.70
• 2023: 4.07
• 2022: 2.24
• 2021: 2.74

Alivus Life Sciences Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Alivus Life Sciences Ltd P/S ratio currently stands at 5.59, an important part of Alivus Life Sciences Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 5.59
• 2023: 4.19
• 2022: 2.23
• 2021: 2.55

The rising Alivus Life Sciences Ltd P/S ratio indicates improved revenue valuation by investors.

Alivus Life Sciences Ltd Price to Cash Flow Ratio (P/CF)

The Alivus Life Sciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 32.25.

Historical Alivus Life Sciences Ltd Price to Cash Flow Ratio:

• 2024: 32.25
• 2023: 22.35
• 2022: 14.58
• 2021: 8.93
• 2020: 0

The rising Alivus Life Sciences Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Alivus Life Sciences Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Alivus Life Sciences Ltd EV currently stands at ₹127.74B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 127.74B
• 2023: 92.28B
• 2022: 45.08B
• 2021: 48.86B

Alivus Life Sciences Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Alivus Life Sciences Ltd EV/EBITDA ratio is currently 18.74, a key metric in Alivus Life Sciences Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 18.74
• 2023: 13.70
• 2022: 7.05
• 2021: 7.94

Higher Alivus Life Sciences Ltd EV/EBITDA suggests premium valuation.

Alivus Life Sciences Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Alivus Life Sciences Ltd D/E ratio is currently 0.02, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.02
• 2023: 0.01
• 2022: 0.01
• 2021: 0

Alivus Life Sciences Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Alivus Life Sciences Ltd ROE currently stands at 18.86%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 18.86
• 2023: 21.07
• 2022: 22.28
• 2021: 29.83

Alivus Life Sciences Ltd maintains stable profitability levels.

Alivus Life Sciences Ltd Ratios Analysis Summary

The Alivus Life Sciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Alivus Life Sciences Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Alivus Life Sciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.